Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

419.60 -4.66 (-1.10%)
Streaming Delayed Price Updated: 1:36 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Via The Motley Fool
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline. 
Via Benzinga
Exposures Product Safety
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Via The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2025
Via The Motley Fool
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months. 
Via Benzinga
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
Exposures Product Safety
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Via The Motley Fool
Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK... 
Via Talk Markets
Topics Stocks / Equities
3 No-Brainer Stocks to Buy on the Latest Sell-Off
Via The Motley Fool
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients. 
Via Benzinga
Exposures Product Safety
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Via The Motley Fool
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock. 
Via Investor's Business Daily
Exposures Product Safety
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.